Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219306 | 1.00 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1SLC7A5PTGS1 | |
| SCHEMBL2219303 | 1.00 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1SLC7A5PTGS1 | |
| SCHEMBL7972265 | 0.83 | GABRP (0.47) | SLC1A3SLC1A2SLC1A1HTR2ASRD5A2 | |
| Hydrochloric Acid SCHEMBL7972261 | 0.82 | GABRP (0.46) | SLC1A3SLC1A2SLC1A1HTR2ASRD5A2 | |
| SCHEMBL14669359 | 0.80 | SLC7A5 (0.51) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL5200313 | 0.80 | SLC7A5 (0.79) | SLC1A3SLC1A2SLC1A1SLC7A5PTGS1 | |
| Phenylalanine SCHEMBL7741736 | 0.80 | SLC7A5 (0.79) | SLC1A3SLC1A2SLC1A1SLC7A5PTGS1 | |
| Dl-Phenylalanine SCHEMBL7321619 | 0.79 | SLC7A5 (0.76) | SLC1A3SLC1A2SLC1A1SLC7A5PTGS1 | |
| SCHEMBL7199568 | 0.78 | NPC1 (0.46) | SLC1A3SLC1A2SLC1A1HTR2ASRD5A2 | |
| SCHEMBL7199571 | 0.78 | NPC1 (0.46) | SLC1A3SLC1A2SLC1A1HTR2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344529-B1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA SAS (FR) | 2013-06-05 | — | — | EP | claimed |
| CN-102171246-A | Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof | IPSEN PHARMA SAS | 2011-08-31 | — | — | CN | claimed |
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-21 | — | — | US | claimed |
| EP-2344529-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-20 | — | — | EP | claimed |
| WO-2010037930-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2010-04-08 | — | — | WO | claimed |
| EP-2168983-A1 | New octapeptide compounds and their therapeutic use | IPSEN PHARMA (FR) | 2010-03-31 | — | — | EP | claimed |
| US-9382306-B2 | Octapeptide compounds derived from somatostatin and the therapeutic use thereof | IPSEN PHARMA S.A.S. (FR) | 2016-07-05 | — | — | US | disclosed |
| CN-102171246-B | Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof | IPSEN PHARMA SAS | 2015-04-08 | — | — | CN | disclosed |
| EP-2344529-B1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA SAS (FR) | 2013-06-05 | — | — | EP | disclosed |
| CN-102171246-A | Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof | IPSEN PHARMA SAS | 2011-08-31 | — | — | CN | disclosed |
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2344529-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037930-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2010-04-08 | — | — | WO | disclosed |
| EP-0049628-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH, USEFUL AS LHRH ANTAGONISTS, METHODS OF MAKING THEM, AND THEIR PHARMACEUTICAL USES | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0021234-B1 | NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF LUTEINIZING HORMONE RELEASING HORMONE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178013-A1 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF | SSTR5, SSTR1, SSTR3 | SLC1A3 140/4885SLC1A2 166/4885SLC1A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.